Drug Sponsors

GlaxoSmithKline sells brands, plant to Aspen Group

Monday, September 30, 2013 02:50 PM

GlaxoSmithKline has reached agreement to sell its thrombosis brands, Arixtra and Fraxiparine, and the Notre-Dame de Bondeville (NDB) manufacturing site to the Aspen Group, a South African pharmaceuticals company, for $1.13 billion in cash, of which $161.9 million relates to inventory. 

More... »

WIRB Copernicus Group

Ipsen to relocate R&D activities to Cambridge, Mass.

Friday, September 27, 2013 10:28 AM

Ipsen plans to relocate its U.S. R&D operations to Cambridge, Mass., in 2014. This site will be key for innovation in targeted therapies across Ipsen's specialty areas as well as a center of excellence for peptides. The move also brings Ipsen closer to several key partners based in the Cambridge area, including prominent hospital centers, medical schools, biotech companies and universities, thereby further promoting and facilitating partnerships and open innovation.

More... »

Servier makes offer for all shares of Egis Pharmaceuticals

Wednesday, September 25, 2013 12:31 PM

Servier Group has announced a voluntary public offer (to be made by its wholly-owned subsidiary Arts et Techniques du Progrès) to purchase all outstanding shares in its majority-owned subsidiary Egis Pharmaceuticals for $126 per share in cash.

More... »

Sysmex acquires Inostics

Wednesday, September 25, 2013 12:29 PM

Privately-held biotech company Indivumed, based in Hamburg, Germany, has announced that Inostics and its Baltimore-based subsidiary have been sold to Sysmex, a developer and manufacturer of instruments, reagents and software needed for in-vitro diagnostics, headquartered in Japan.

More... »

PRA, RPS merger completed

Wednesday, September 25, 2013 12:23 PM

CRO PRA International has completed its merger with ReSearch Pharmaceutical Services (RPS) and the closing of the acquisition by Kohlberg Kravis Roberts.  

More... »

GSK inks agreement with BARDA to supply anthrax treatment

Friday, September 20, 2013 11:32 AM

GlaxoSmithKline has signed a new four-year contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), for the provision of its inhalation anthrax treatment, raxibacumab. The U.S. government is purchasing the medicine as a counter measure against a potential bioterrorist attack.

More... »

Medtronic opens Ireland Innovation Center

Wednesday, September 18, 2013 12:44 PM

Medtronic, a Minneaplis, Minn.-based medical technology provider, has opened a new Customer Innovation Center (CIC) in Galway, Ireland, providing state-of-the-art facilities for physicians and Medtronic engineers to develop new therapies that will improve clinical outcomes, provide economic value and increase access to quality healthcare for patients around the world.

More... »

Boston Scientific opens China Innovation Center

Wednesday, September 18, 2013 11:25 AM

Boston Scientific, a global medical technology company, has opened the China branch of the Boston Scientific Institute for Advancing Science (IAS) as well as its new Innovation Center. Boston Scientific expects to foster local talent while sustainably developing innovative technologies uniquely suited to the China market.

More... »

Cardiome, Tzamal Medical form commercialization agreement

Wednesday, September 18, 2013 10:57 AM

Cardiome Development, a subsidiary of Cardiome Pharma, and Tzamal Medical Group are collaborating to sell and distribute Brinavess (vernakalant intravenous) exclusively in Israel. Tzamal Medical, a private group of companies providing medical devices and equipment for the healthcare industry, has agreed to specific annual commercial goals for Brinavess, which was approved in Europe for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. Financial details of the agreement have not been disclosed.

More... »

Chiesi to acquire 100% of Cornerstone Therapeutics

Wednesday, September 18, 2013 09:04 AM

European pharma company Chiesi Farmaceutici will acquire 100% of Cornerstone Therapeutics, a North Carolina-based specialty pharmaceutical company commercializing products for the U.S. hospital and adjacent specialty markets.

More... »

Subscribe to The CenterWatch Monthly



Browse by:


August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs